Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,302.55 +55.87 (+1.06%) Dow
39,850.72 +292.61 (+0.74%) Nasdaq
16,740.76 +229.58 (+1.39%) Bitcoin USD
65,667.09 +4,190.16 (+6.82%) CMC Crypto 200
1,385.16 +117.21 (+9.23%)
BIIB Oct 2024 170.000 put
| Previous close | 4.0300 |
| Open | 1.5000 |
| Bid | 0.4000 |
| Ask | 1.4000 |
| Strike | 170.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.3400 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 118 |
ZacksBiogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
- Reuters
UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
Eisai and partner Biogen said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer's disease drug Leqembi. The companies are seeking the Food and Drug Administration's (FDA) approval of a weekly dose of Leqembi to be given as an under-the-skin injection. Under a rolling submission the regulator assesses the data as and when it becomes available, and the process continues until there is enough data for a formal marketing application.
GlobeNewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dos
